Discover Our Projects

We work to achieve two main value milestones:
Preclinical proof of concept in relevant animal models or Clinical proof of concept in patients.

Image

OUR PIPELINE

    • Therapeutics
    • Preclinical POC
    • Clinical POC
    • Partnered
  • Unique, disease modifier mechanism of action to prevent and treat mucositis caused by cancer therapy. Strong preclinical evidence that supports the MoA. Phase II results in 2018. Fast to market potential.

  • Fixed-dose combination of known active ingredients for the treatment of mild to moderate muscular pain associated with sports practice or temporo-mandibular joint disorder. Clinical PoC results in 2018.

  • Validated and safe API for the treatment of atopic dermatitis and psoriasis using an innovative topical formulation. Clinical PoC results by 2018.

  • Injectable product with strong nephroprotective activity in animal models. Clinical PoC by 2019

  • Clinical stage product with proven safety repositioned to treat aortic aneurism. Very solid preclinical evidence. Clinical PoC in Marfan syndrome patients by 2021

  • Immunomodulatory naturally occurring blood-protein that induces tolerogenesis in dendritic cells, to treat rheumatoid arthritis, lupus nephritis, IBD and other autoimmune diseases. Preclinical candidate ready to start regulatory development

  • Human naturally occurring protein that increases survival and ameliorates behavior and histochemical readouts. Preclinical PoC in ALS model in 2016.

    OBJECT
    Previous results showed that, after intraperitoneal administration of 50 ng of SP14037-01 to no symptomatic mSOD1G93A mice, treated animals resulted in increased survival, delayed onset of disease and improved the general state.
    In the current project, it is proposed to study the effect of SP14037-01 when administered to symptomatic SOD1G93A mice in early stages of illness (from day 50, subcutaneous administration, 3 times per week).
    CONCLUSIONS
    Therapeutic potential of the compound was evaluated in SOD1G93A ALS mouse model. The drug was delivered subcutaneously in postnatal day 50 female/male mice. Behavioural tests (rotarod, catwalk gait and open field analysis system), electromyography, onset of disease, mouse survival, immunohistochemical, histological and NMJ analysis were used to evaluate the effect of treatment in the ALS model.
    Marginal but not significant efficacy of tested compound was observed with Catwalk gait analysis and NMJ pathology. Other parameters showed no significant effects of the treatment in SOD1G93A.

    El projecte té el suport d’ACCIÓ, l’agència per a la competitivitat de l’empresa, a través del programa Nuclis de Recerca Industrial i Desenvolupament Experimental,  finançat a través del Fons Europeu de Desenvolupament Regional (FEDER) amb la finalitat de Promoure el desenvolupament  tecnològic, la innovació i una investigació de qualitat.

     

  • First in class dual antagonist mechanism, highly selective and potent, orally available. Relevant proof of concept package in preclinical models and safety data to give  a solid preclinical candidate by 1Q 2018.

  • Recombinant protein for the local treatment of traumatic muscle injuries, with potential application in sports-related injuries. Preclinical proof of concept in animal models, including sheep, shows acceleration of muscle force recovery without inducing fibrosis.

  • Peptide with novel, targeted immunomodulatory mechanism of action, superior safety profile over current biologics, and displaying a low manufacturing cost. In vivo evidence in IBD animal model. SP15008 targets SAA and IL1β. Next relevant value milestone: Preclinical PoC with an industrially scalable formulation in 2019.

    Project co-financed by FEDER
    With the support of the Centro para el Desarrollo Tecnológico Industrial (CDTI)


Know more about Spherium Biomed

 

Either if you have a project to license,
or you are looking for biomedical projects...

CONTACT US AT:info@spheriumbiomed.com